Upstream Bio is set to deliver additional clinical findings from its Phase 2 VIBRANT trial of verekitug, aimed at treating chronic rhinosinusitis with nasal polyps. The data, which centers on a responder analysis, will be presented at the EAACI 2026 Congress in Istanbul on June 14, 2026.